Treatment of dMMR Metastatic Colorectal Cancer in 2025
Canadian Oncology Today · 2025
DOI: 10.58931/cot.2025.2340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Renata D’Alpino Peixoto und 1 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), accounting for approximately 4–5% of cases, represents a distinct molecular subgroup with unique therapeutic implications. These malignancies are characterized by a high mutational burden and increased immune cell infiltration, making them particularly responsive to immune checkpoint inhibitors (ICI). Conversely, this subgroup tends to be less sensitive to traditional chemotherapy.
Zitieren
APA
Peixoto, R. D., & Amaral, T. M. D. (2025). Treatment of dMMR Metastatic Colorectal Cancer in 2025. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2340
Vancouver
Peixoto RD, Amaral TMD. Treatment of dMMR Metastatic Colorectal Cancer in 2025. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2340
BibTeX
@article{Peixoto2025,
author = {Peixoto, Renata D’Alpino and Amaral, Thiago Miranda do},
title = {Treatment of dMMR Metastatic Colorectal Cancer in 2025},
journal = {Canadian Oncology Today},
year = {2025},
doi = {10.58931/cot.2025.2340}
}
EUVIMED